These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 9156411)
1. Prevention of recurrences after deep venous thrombosis: role of low-molecular-weight heparins. Pini M Semin Thromb Hemost; 1997; 23(1):51-4. PubMed ID: 9156411 [TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369 [TBL] [Abstract][Full Text] [Related]
3. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience]. Míka P; Behounek J; Skoták M; Nevsímal L Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102 [TBL] [Abstract][Full Text] [Related]
5. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis. Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415 [TBL] [Abstract][Full Text] [Related]
6. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Ramacciotti E; Araújo GR; Lastoria S; Maffei FH; Karaoglan de Moura L; Michaelis W; Sandri JL; Dietrich-Neto F; Thromb Res; 2004; 114(3):149-53. PubMed ID: 15342210 [TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis. Holzheimer RG Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403 [TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850 [TBL] [Abstract][Full Text] [Related]
9. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Douketis J; Cook D; Meade M; Guyatt G; Geerts W; Skrobik Y; Albert M; Granton J; Hébert P; Pagliarello G; Marshall J; Fowler R; Freitag A; Rabbat C; Anderson D; Zytaruk N; Heels-Ansdell D; Crowther M; Arch Intern Med; 2008 Sep; 168(16):1805-12. PubMed ID: 18779469 [TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparins for the treatment of deep-vein thrombosis. Cziraky MJ; Spinler SA Clin Pharm; 1993 Dec; 12(12):892-9. PubMed ID: 8137606 [TBL] [Abstract][Full Text] [Related]
11. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis. Holmström M; Aberg W; Lockner D; Paul C Thromb Haemost; 1999 Oct; 82(4):1222-6. PubMed ID: 10544902 [TBL] [Abstract][Full Text] [Related]
12. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Monreal M; Lafoz E; Olive A; del Rio L; Vedia C Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649 [TBL] [Abstract][Full Text] [Related]
13. Treatment of deep vein thrombosis with low-molecular-weight heparins: a consensus statement of the Gesellschaft für Thrombose-und Hämostaseforschung (GTH). Harenberg J; Schmitz-Huebner U; Breddin KH; Hass S; Heinrich F; Heinrichs C; Kienast J; Roebruck P; Theiss W; Wenzel E Semin Thromb Hemost; 1997; 23(1):91-6. PubMed ID: 9156416 [TBL] [Abstract][Full Text] [Related]
14. [Low molecular weight heparin: favorable effect profile for prevention and therapy of venous thrombosis]. Marbet GA Ther Umsch; 1992 Dec; 49(12):843-9. PubMed ID: 1336627 [TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight heparin in outpatient treatment of DVT. Yeager BF; Matheny SC Am Fam Physician; 1999 Feb; 59(4):945-52. PubMed ID: 10068716 [TBL] [Abstract][Full Text] [Related]
16. The role of low molecular weight heparin in total knee arthroplasty. Iobst CA; Friedman RJ Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695 [TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537 [TBL] [Abstract][Full Text] [Related]
19. The effect of enoxaparin in prevention of deep venous thrombosis in hip and knee surgery--a comparison with the dihydroergotamine-heparin combination. Perhoniemi V; Vuorinen J; Myllynen P; Kivioja A; Lindevall K Ann Chir Gynaecol; 1996; 85(4):359-63. PubMed ID: 9014067 [TBL] [Abstract][Full Text] [Related]
20. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage. Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]